Discover 3 Asian Penny Stocks With Market Caps Larger Than US$100M

As Asian markets continue to navigate a landscape marked by geopolitical tensions and economic shifts, investors are increasingly exploring diverse opportunities across the region. Penny stocks, often seen as smaller or newer companies with potential for growth, remain an intriguing segment for those seeking untapped value. In this article, we explore three Asian penny stocks that stand out for their financial strength and potential to offer compelling investment opportunities in today's evolving market context.

Top 10 Penny Stocks In Asia

Name	Share Price	Market Cap	Rewards & Risks
Lever Style (SEHK:1346)	HK$1.44	HK$890.67M	✅ 4 ⚠️ 1 View Analysis >
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)	THB2.18	THB915.6M	✅ 3 ⚠️ 3 View Analysis >
TK Group (Holdings) (SEHK:2283)	HK$2.58	HK$2.14B	✅ 4 ⚠️ 1 View Analysis >
Atlantic Navigation Holdings (Singapore) (Catalist:5UL)	SGD0.123	SGD64.39M	✅ 2 ⚠️ 3 View Analysis >
Halcyon Technology (SET:HTECH)	THB2.76	THB828M	✅ 2 ⚠️ 3 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD3.67	SGD14.44B	✅ 5 ⚠️ 1 View Analysis >
NagaCorp (SEHK:3918)	HK$4.66	HK$20.61B	✅ 5 ⚠️ 1 View Analysis >
Livestock Improvement (NZSE:LIC)	NZ$1.00	NZ$137.01M	✅ 2 ⚠️ 5 View Analysis >
Bosideng International Holdings (SEHK:3998)	HK$4.40	HK$51.11B	✅ 4 ⚠️ 2 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.87	NZ$237.15M	✅ 3 ⚠️ 1 View Analysis >

Click here to see the full list of 950 stocks from our Asian Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Venus Medtech (Hangzhou) (SEHK:2500)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Venus Medtech (Hangzhou) Inc. is involved in the research, development, manufacturing, and sale of bioprosthetic heart valves both in Mainland China and internationally, with a market cap of approximately HK$1.37 billion.

Operations: The company's revenue is generated entirely from its medical products segment, amounting to CN¥427.25 million.

Market Cap: HK$1.37B

Venus Medtech (Hangzhou) Inc. has been actively advancing its innovative Cardiovalve transcatheter valve replacement system, targeting mitral and tricuspid regurgitation. Recent clinical trials in Europe have shown promising results, with high procedural success rates and significant improvements in patient outcomes over 12 months. The company is focused on accelerating regulatory approvals to enhance market access for its products. Despite being unprofitable with a negative return on equity, Venus Medtech's strategic focus on R&D and global expansion positions it as a potentially valuable player in the medical device sector, supported by an experienced management team and board of directors.

• Navigate through the intricacies of Venus Medtech (Hangzhou) with our comprehensive balance sheet health report here.
• Assess Venus Medtech (Hangzhou)'s future earnings estimates with our detailed growth reports.

Tian An China Investments (SEHK:28)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tian An China Investments Company Limited is an investment holding company that focuses on investing in, developing, and managing properties across the People's Republic of China, Hong Kong, and the United Kingdom with a market cap of approximately HK$6.98 billion.

Operations: The company's revenue segments include Property Development generating HK$7.61 billion, Healthcare contributing HK$1.54 billion, and Property Investment with HK$573.86 million in revenue.

Market Cap: HK$6.98B

Tian An China Investments demonstrates a robust financial position with short-term assets of HK$21.2 billion surpassing both its short and long-term liabilities. Despite a low return on equity at 6.8%, the company has achieved significant earnings growth of 186.8% over the past year, outpacing industry trends, and maintains high-quality earnings. Its debt management is commendable, with debt levels well covered by operating cash flow and interest payments comfortably managed by EBIT at 230.3x coverage. Trading significantly below estimated fair value, Tian An's seasoned board and management bolster its strategic outlook in property development across key regions.

• Unlock comprehensive insights into our analysis of Tian An China Investments stock in this financial health report.
• Examine Tian An China Investments' past performance report to understand how it has performed in prior years.

Tongdao Liepin Group (SEHK:6100)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tongdao Liepin Group, with a market cap of HK$2.21 billion, is an investment holding company that offers talent acquisition services in the People’s Republic of China.

Operations: The company generates its revenue from talent services, amounting to CN¥2 billion.

Market Cap: HK$2.21B

Tongdao Liepin Group, with a market cap of HK$2.21 billion, shows financial resilience as its short-term assets (CN¥3.0 billion) comfortably cover both short and long-term liabilities. The company boasts high-quality earnings and has achieved an impressive 345.7% earnings growth over the past year, surpassing industry averages despite a low return on equity of 6.8%. Debt management is strong, with cash exceeding total debt and operating cash flow covering debt well at 177.9%. Recent share repurchase initiatives aim to enhance net asset value per share and earnings per share, reflecting strategic capital allocation efforts amidst stable weekly volatility (6%).

• Click to explore a detailed breakdown of our findings in Tongdao Liepin Group's financial health report.
• Gain insights into Tongdao Liepin Group's outlook and expected performance with our report on the company's earnings estimates.

Summing It All Up

• Navigate through the entire inventory of 950 Asian Penny Stocks here.
• Seeking Other Investments? Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com